Table II.
Plasmids Used in This Work
| Plasmid | Description | Source | ||
|---|---|---|---|---|
| pJG103 | 2 μm SEC22 URA3 | S. Ferro-Novick | ||
| pSFN2d | 2 μm BET1 URA3 | S. Ferro-Novick | ||
| pAN109 | 2 μm BOS1 URA3 | S. Ferro-Novick | ||
| pNB167 | 2 μm YPT1 URA3 | S. Ferro-Novick | ||
| pGR3 | 2 μm BET3 URA3 | S. Ferro-Novick | ||
| pSED5 | 2 μm SED5 URA3 | H. Pelham | ||
| pSFT1 | 2 μm SFT1 URA3 | H. Pelham | ||
| pNB657 | 2 μm SEC19 URA3 | P. Novick | ||
| pNB142 | 2 μm SEC4 URA3 | P. Novick | ||
| pYEpSNC1 | 2 μm SNC1 LEU2 | J. Gerst (Weismann Institute of Science, Rehovot, Israel) | ||
| pYEpSNC2 | 2 μm SNC2 LEU2 | J. Gerst | ||
| pSLY1-LEU2 | 2 μm SLY1 LEU2 | H.D. Schmitt (Max Planck Institute, Gottingen, Germany | ||
| pSK60 | 2 μm YKT6 URA3 | This laboratory | ||
| pSK47 | 2 μm USO1 URA3 | This laboratory | ||
| pPI2 | 2 μm VTI1 URA3 | This laboratory | ||
| pSK101 | 2 μm BOS1 URA3 | This study | ||
| pSV17 | 2 μm SEC35 URA3 | This study | ||
| pNB166 | CEN YPT1 URA3 | S. Ferro-Novick | ||
| pYCp50-SLY1-20 | CEN SLY1-20 URA3 | H.D. Schmitt | ||
| pSV11 | CEN SLY1-20 URA3 | This study | ||
| pSV15 | CEN SEC35 LEU2 | This study | ||
| pSV16 | CEN SEC35 URA3 | This study | ||
| pSV23 | CEN YGR122w LEU2 | This study | ||
| pSV42 | CEN sec35-1 URA3 | This study | ||
| pSV18 | YIp SEC35 URA3 | This study | ||
| pSV31 | YIp sec35Δ LEU2 | This study | ||
| pSV29 | GST-Sec35p | This study | ||
| pSV20 | His6-Sec35p | This study | ||
| pRS424 | YEp URA3 | P. Hieter (Johns Hopkins School of Medicine, Baltimore, MD) | ||
| pRS415 | YCp LEU2 | P. Hieter | ||
| pRS416 | YCp URA3 | P. Hieter | ||
| pRS305 | YIp LEU2 | P. Hieter | ||
| pRS306 | YIp URA3 | P. Hieter | ||
| pGEX-2T | GST-fusion vector | Pharmacia Biotech, Inc., Piscataway, NJ | ||
| pQE-30 | His6-fusion vector | QIAGEN, Inc., Santa Clarita, CA |